Lv53
1580 积分 2024-01-09 加入
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
3小时前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
14天前
已完结
Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006)
3个月前
已完结
Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006)
3个月前
已关闭
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
3个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
3个月前
已完结
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
3个月前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
3个月前
已完结
[Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma]
7个月前
已完结
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
8个月前
已完结
皖公网安备34019202002308
